CONTEXT THERAPEUTICS INC
(NASDAQ: CNTX)
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
1.480
+0.120
(+8.82%)
Range
- - -
(-%)
Open
-
Previous Close
1.360
Bid Price
0.671
Bid Volume
10
Ask Price
0.698
Ask Volume
12
Volume
21,318
Value
-
Remark
View All Events
Loading Chart...
Please login to view stock data and analysis